Aptamer Sciences Inc.
Financials
Valuation Metrics
Aptamer Sciences Inc.'s Market Cap is ₩580B. At end of 2025 it was ₩463B. Ranked #1600 of 2,436 in KR market (top 66%), #941 of 1,649 on KOSDAQ (top 57%), #178 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.99B KRW | KR#1,600/2,436 Sec#178/234 |
| Revenue | 3.62B KRW | KR#2,365/2,436 Sec#204/234 |
| Net Income | -8.80B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 45.93B KRW | KR#2,221/2,436 Sec#203/234 |
| Net Assets | 26.74B KRW | KR#2,195/2,436 Sec#200/234 |
| Employees | 55 | KR#1,991/2,436 Sec#180/234 |
| Value | ||
| P/B | 2.17x | KR#2,010/2,436 Sec#151/234 |
| P/S | 16.03x | KR#2,322/2,436 Sec#180/234 |
| FCF Yield | -16.71% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -32.91% | KR#2,190/2,436 Sec#180/234 |
| ROA | -19.16% | KR#2,224/2,436 Sec#175/234 |
| Op. Margin | -195.10% | KR#2,338/2,436 Sec#186/234 |
| Revenue Growth | 19.02% | KR#664/2,436 Sec#64/234 |
| Financial Health | ||
| Debt Ratio | 71.75% | KR#242/2,436 Sec#33/234 |
| Total Debt | 11.83B KRW | KR#1,562/2,436 Sec#142/234 |
| FCF | -9.69B KRW | KR#1,703/2,436 Sec#146/234 |
| Cash | 18.90B KRW | KR#1,269/2,436 Sec#94/234 |
| Current Ratio | 1.65x | KR#1,190/2,436 Sec#130/234 |
| Performance | ||
| 1Y Return | -10.63% | KR#911/2,436 Sec#63/234 |
| 1M Return | 15.85% | KR#156/2,436 Sec#8/234 |
| From 52W High | -52.45% | KR#1,196/2,436 Sec#97/234 |
| 1Y MDD | -64.45% | KR#1,667/2,436 Sec#140/234 |
| Trading | ||
| Foreign Own. | 2.06% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -252 KRW | KR—/2,436 Sec—/234 |
| BPS | 649 KRW | KR#2,367/2,436 Sec#225/234 |
Company Info
Aptamer Sciences, established in 2011 as a POSTECH spin-off, listed on KOSDAQ in 2020 and expanded into the Contract Research Organization (CRO) business by acquiring ISS in 2024. The company is developing solid and blood cancer therapeutics leveraging its aptamer technology platform, with its flagship product, Aptodetect Lung, being an excellent in-vitro diagnostic kit. Aptamer Sciences is further building expertise in biopharmaceutical analysis and establishing a comprehensive new drug development system to advance next-generation anticancer drug development.